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Abstract
Background: Patients after myocardial infarction (MI) are at greater risk of sudden cardiac
death (SCD) than people in the overall population. The aim of this study was to detect muta-
tions, including intronic ones, in the KCNQ1 gene coding for proteins of cardiac potassium
channels and evaluate their possible effects on the clinical course in patients after MI.
Methods: The study group was composed of 100 Polish patients after MI, which included
27 women (mean age 69 years) and 73 men (mean age 67 years). All patients underwent clinical
examinations and genetic tests. The genetic test results have been correlated with the clinical
data. The following parameters have been chosen as endpoints for this survey: sudden cardiac
arrest (SCA) or SCD, complex ventricular arrhythmia, QT interval and QT dispersion values
assessed during 24-hour Holter ECG monitoring in relation to ventricular arrhythmias as well
as the minimum and maximum heart rate (HR) observed during the examination.
Results: Six new mutations in the KCNQ1 gene: C2505734T, A2753831C in exons and
C2505846A, G2753881A, T2755854C, T2755875G in introns. Detected intronic mutations
in patients after MI were related to a worse clinical course and frequent occurrence of SCA.
Conclusions: The novel intronic mutations may have a significant influence on the clinical
course of the disease. (Cardiol J 2008; 15: 252–260)
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Introduction
Mutations in potassium channel genes are the
most frequent genetic abnormalities in patients with
congenital long QT syndrome (LQTS). To date,
more than 100 families with mutations in this gene
have been reported, most of them with their own
specific mutations. In general the majority of these
mutations are missed. However, other types of
mutations, such as deletions, frame-shifts and spli-
ce-donor errors have also been reported [1–5]. The
protein produced from the KCNQ1 gene interacts
with proteins in the KCNE family (such as KCNE1)
to form functional potassium channels. Four alpha
subunits, each produced from the KCNQ1 gene,
form the structure of each channel. A combination
of normal and mutant KCNQ1 alpha-subunits has
been found to form abnormal channels; hence mu-
tations associated with the KCNQ1 gene may re-
sult in the prolongation of the cellular repolariza-
tion phase that may clinically predispose patients
with mutations to arrhythmic events. In patients
after myocardial infarction the arrhythmic events
are more common than in the normal population [6].
It is important to define the subgroup of patients
who may be prone to life-threatening arrhythmias.
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It is possible that the presence of specific altera-
tions in the genotype, occurring in the form of mu-
tations or polymorphisms of single nucleotides, may
constitute such indicators for higher-risk groups,
independently of other clinical factors. The gene-
tic abnormalities found in those patients may help
us to understand the mechanism leading to arrhy-
thmic events and serve as an indicator of high risk
for sudden cardiac death.
The aim of this study was therefore to detect
mutations in the KCNQ1 gene in patients after
myocardial infarction in order to see whether they
have any effect on electrophysiological predictors
of arrhythmia, such as QT interval length and QT
dispersion, and subsequently to assess the rela-
tionship between the detected genetic alterations
and the clinical course of the disease. In addition,
we decided to try and assess the clinical signifi-
cance of the detected mutations in introns of the
KCNQ1 gene.
Methods
The protocol of this research study has been
approved by the Commission for Bioethics of the
Military Medical Chamber in Warsaw. All patients
expressed in writing an informed consent to take
part in this study.
The studied population included 27 women
(age range: 54–79 year old) and 73 men (age range:
43–83 year old) after non-recent (> 3 months)
myocardial infarction (MI). The diagnosis of MI was
made if elevated troponin or CK-MB levels and either
ischemic symptoms or electrocardiographic changes
were noted. The exclusion criteria were as follows:
recent MI, anginal symptoms at rest, electrolyte im-
balance, QT prolonging medications, non-interpre-
table ECG. All patients were examined (past and
present history, physical examination, standard blo-
od tests including sodium, calcium, potassium and
magnesium concentrations, 12-lead ECG, 12-lead
Holter ECG monitoring and echocardiography) at
baseline and after 12 months of follow-up. The blo-
od was drawn for the genetic analysis at baseline
visit.
24-hour Holter ECG monitoring
Twelve lead Holter monitoring systems (Mor-
tara Instruments H-Scribe 2) at the sweep speed
of 25 mm/s was employed. The following parame-
ters were assessed:
— heart rhythm disturbances with the ventricu-
lar arrhythmia classification according to the
Lown classification;
— ST segment changes suggesting ischemia;
— QT interval length and dispersion.
The QT interval (from the start of the QRS
complex to the end of the T wave) was measured
in all leads. If the U wave was present the end of
the QT interval was defined as the intersection
point of the tangent to the visible part of the de-
scending part of the T-wave. The QT interval du-
ration was corrected for heart rate (QTc) accor-
ding to the Bazzet’s formula if the heart rate (HR)
was between 50–120/min or Hodges formula if it
was outside this range. The QT dispersion (QTd)
was calculated as the difference between the ma-
ximal QT (QTmax) and minimal (QTmin) interval
duration.
The measurements of QTmax, maximal QTc
and QTd were performed during daytime and be-
tween 10 PM and 6 AM:
— at minimal and maximal heart rate;
— in the sinus beat before the last normal sinus
beat preceding the ventricular extrasystole,
ventricular couplet or ventricular tachycardia
— called “pre-sinus beat” and designated by
“QT1”;
— in the last sinus beat before the above mentio-
ned ventricular arrhythmia — called “pre-ven-
tricular beat” and designated by “QT2”.
Then the DQT for each patient was calculated
as the difference between QT2 and QT1 time po-
ints for QTmax, QTc max, QTd respectively. The
mean difference of DQT for all the patients in the
group was subsequently estimated.
Echocardiography
The echocardiographic evaluation (M-mode,
2D and Doppler) included the global and regional
contractility, left ventricular ejection fraction (EF)
calculation according to the Simpson formula, valvu-
lar and pericardial assessment. The General Elec-
tric device (System Five) was used for all studies.
DNA analysis
The genetic analysis was conducted in the
Kucharczyk TE Company (Warsaw, Poland). Geno-
mic DNA from 100 patients were extracted from
peripheral blood leucocytes (100 µl of frozen blood
was used) with Blood Mini Kit (A&A Biotech,
Gdańsk, Poland). Isolation was performed according
to the manufacturer’s procedure. Regions which
were known to contain genetic alterations were
chosen for amplification. Twelve regions of KCNQ1
gene were amplified. Amplification was performed
according to the procedure listed in [5, 7, 8] The
primers are presented in Table 1.
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The PCR products were separated on agarose
electrophoresis to check for their specificity. Next
2800 PCR products were analyzed by multitempe-
rature single strand conformation polymorphism
(MSSCP) [9] technique for single mutation and po-
lymorphisms presence.
The MSSCP conditions were optimized for
each analyzed region. MSSCP was performed on
6 to 10%T polyacrylamide gels, 3.3%C in 0.75 ×
× TBE buffer. For some regions glycerol was ad-
ded to polyacrylamide gel 5% w/v. MSSCP analy-
sis was performed in DNA Pointer System in 0.5 ×
× TBE buffer. Temperature profile of electropho-
resis was 35–15–5°C. Electrophoresis was perfor-
med with 40 W of electrical power, 10 min of pre-
electrophoresis (40 W at 35°C) was performed be-
fore applying samples onto the gel. At the start
samples were separated for 10 min at 100 V for con-
centration. After that step MSSCP separation was
performed. Optimized MSSCP electrophoresis con-
ditions are presented in Table 2.
The PCR products that have altered MSSCP
mobility were selected and sequenced. Twenty
ng DNA/100 bp of PCR product was used as a ma-
trix for sequencing reaction. Both strands were se-
quenced in PCR products the sequencing of which
revealed a genetic alternation.
Genetic alterations were identified using the
BLAST (Basic Local Alignment Search Tool) program
and its BLASTN version as well as UCSC (University
of California Santa Cruz) Genome Bioinformatics and
NCBI (National Center for Biotechnology Information)
databases of single nucleotide polymorphisms (SNPs).
Study’s clinical endpoints
The following parameters have been chosen as
endpoints for this study:
— occurrence of sudden cardiac arrest or sudden
cardiac death (SCD);
— presence of complex ventricular arrhythmia in
the form of non-sustained or sustained ventri-
cular tachycardia (respectively nsVT and sVT)
or ventricular fibrillation (VF);
Table 1. Primers used for PCR reaction for
amplification of fragments of KCNQ1 gene.
Exon Primer sequence Reference
1 F:TCGCCTTCGCTGCAGCTC
R:TCCCCCACCAGCTCTCAG [2]
1a F:CTACCTGGGGGCGGGGCTGA
R:GTGTGGGCAAGGGGCTGGGA [2]
3 F:CCCTTCCCCAGACGAGAGCA
R:CTCCACCCATCCCAGCACAT [2]
4 F:AGGGGCAGGGGCAGGGACAC
R:CGGGGCCTCAGCGCATCTCA [2]
5 F:TCGCTGGGACTCGCTGCCTT
R:TGTCCTGCCCACTCCTCAGCCT [2]
6 F:GGGTTTGGGTTAGGCAGTTGG
R:AGCCACCCCAGGACCCCAG [2]
11 F:CAGGGGCAGTGAGGGGATGA
R:GTGGCTTGGGGGCGGAGG [2]
12 F:CACTGCCTGCACTTTGAGCC
R:GTGAGGAGAAGGGGGTGGTT [2]
14 F:CCCCCAGCCCTACCACCC
R:GCAGGAGCTTCACGTTCACA [2]
15–1 F:TTCCCACCACTGACTCTCT
R:ACTCTTGGCCTCCCCTCT [2]
15–2 F:GGGATGGGGCTGGGGGA
R:CTGTGCTACTTCCTGGCCAT [2]
15–3 F:TCACTGGCATGGTGGTTGGG
R:GGGGAAATGGTGAGACTGTC [2]
Table 2. Optimised multitemperature single strand conformation polymorphism (MSSCP) conditions
for KCNQ1 gene.
Exon PCR Acrylamide Glycerole MSSCP
product size concentration (%)  concentration (%)  temperature profile [°C]
1a 510 6 5 35–15–5
1 310 9 5 35–15–5
3 330 8 0 35–15–5
4 300 9 5 35–15–5
5 291 9 5 35–15–5
6 247 9 5 35–15–5
11 270 9 5 35–15–5
12 302 9 5 35–15–5
14 249 9 5 35–15–5
15–1 328 8 0 35–30–25
15–2 9 5 35–15–5
15–3   9 5 35–15–5
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— QT interval and QT dispersion values asses-
sed during 24-hour Holter ECG monitoring in
relation to ventricular arrhythmias as well as
minimum and maximum HR observed during
the examination.
Statistical analysis
The distribution of the data subjected to ana-
lysis was not normal so the non-parametric tests
were used. Spearman’s rank test correlation was
used for interval data. In order to assess the stati-
stical relationship between interval and nominal
data the Mann-Whitney test was employed. The
c2 statistical analysis was used for the nominal data
subsets.
Results
In the population of 100 patients after myocar-
dial infarction several genetic alterations in the
KCNQ1 gene were found. We searched for their
existence both in SNP databases (such as NCBI or
UCSC) and in scientific literature, and found that
they were neither reported as common polymorphi-
sms nor as known mutations. Therefore, since the
variants we detected in our study must be quite rare
in the wild-type population, we conclude that these
genetic alterations are novel mutations.
Among all discovered mutations in the KCNQ1
gene the most widespread was the T2755875G
mutation. According to the UCSC Genome Bioin-
formatics the alteration is located within the ge-
ne’s intron 14. It was found in 19 patients. All pa-
tients were heterozygotes (T/G). The remaining
81 patients were free from this mutation. The cli-
nical data characterizing both groups are presen-
ted in Table 3.
The comparison of the groups with and witho-
ut the T2755875G mutation showed a significantly
higher rate of sudden cardiac arrest, as depicted in
Figure 1, in patients with this mutation despite
a significantly higher left ventricular ejection frac-
tion (55 ± 5% vs. 50 ± 11.6%, p < 0.03). There were
no differences in the SCD rates between groups.
The arrhythmic episodes were not significan-
tly different apart from the higher percentage of
sustained VT in history found in patients with the
mutation (10.5% vs. 2.5% in the control group).
On the other hand, in the analysis of Holter ECG
QT interval parameters we corrected the QT inte-
rval duration for HR using Bazett’s or Hodges’ for-
mule. In the baseline examination the percentage of
Hodges-corrected QT measurements was 9.6% in
the group with the mutation and 7.9% in the group
without, whereas in the follow-up examination the-
se percentages were respectively 8.2% and 9.4%.
Thus, the analysis of the QT interval observed
in Holter ECG recordings obtained during the ba-
seline examination revealed that Bazzet-corrected
QT1c max was shorter in patients with this muta-
tion than in those without. The QT2c max was not
significantly different (Fig. 2, 3). In contrast, Hol-
ter ECG recordings obtained during the follow-up
examination revealed a trend towards longer valu-
es at peak heart rate in patients with the T2755875G
mutation (436 ± 40 ms vs. 412 ± 46 ms, p = 0.06
for QTmax and 70 ± 30 ms vs. 54 ± 21 ms, p =
= 0.06 for QTd). There were no statistical differen-
ces in the QT interval, QT dispersion in relation to
complex ventricular arrhythmia between groups.
The remaining data observed in Holter ECG recor-
dings are presented in Table 4.
An example of MSCCP results is shown in
Figure 4. They concern the KCNQ1 exon 14 and
its bordering intronic regions (mutation T2755875G
in samples 58, 59).
Other mutations
During DNA sequencing a novel mutation
C2505734T was found in the first exon of the
KCNQ1 gene. This is a silent mutation in the 129th
position (V129V). It was found in a patient with
a history of sudden cardiac arrest (SCA). This pa-
tient had also mutations in the KCNQ1 gene introns
— G2753881A in intron 12 and T2755875G in in-
tron 14. He was heterozygotic with regard to all his
mutations (C/T, G/A, T/G) respectively.
In the exon 12 another new mutation
— A2753831C — was found in 2 patients. Both pa-
tients suffered from ventricular arrhythmia after
myocardial infarction. They were heterozygotic
with regard to this mutation (A/C). This is a silent
mutation in the positions 552 (leu552leu), 452
(leu452leu) and 425 (leu425leu), depending on the
protein isoforms.
Furthermore the C2505846A mutation located
in intron 1 has been detected in a heterozygotic pa-
tient who had a SCD during the follow-up. Another
mutation (T2755854C) was found in the KCNQ1
gene intron 14 in a patient with ventricular arrhyth-
mia Lown IVa. This patient was heterozygotic with
regard to the above mentioned mutation (T/C).
Discussion
The patients after myocardial infarction repre-
sent a non-homogenous group with an increased
risk for cardiovascular adverse events including
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arrhythmic episodes and sudden cardiac death. The
QT interval on the surface ECG is a representation
of repolarization time in the ventricle. QT intervals in
humans vary as a function of age, sex, heart rate, heart
disease, and drugs and are generally less than 480 ms.
“Acquired LQTS” describes not one end of
a physiologic spectrum, but rather pathologic QT
interval prolongation, generally to greater than 550–
–600 ms, upon exposure to an environmental stres-
sor and reversion back to normal following withdra-
wal of the stressor. When QT intervals are marke-
dly prolonged, the polymorphic ventricular
tachycardia — torsade de pointes becomes a real
risk. Torsade de pointes can be self-limited or can
degenerate to fatal arrhythmias such as ventricular
fibrillation. It is the potential for torsade de pointes
and sudden cardiac death that has generated such
Figure 1. Percentage of patients with sudden cardiac arrest
episodes in groups with and without T2755875G mutation.
Table 3. Clinical data characterizing groups with and without the T2755875G mutation.
Feature Group with Group without
mutation mutation
Gender (N) Women 2 24
Men 17 57
Mean age (years) Women 68 69
Men 70 66
Myocardial infarction (%) Inferior 73.7 51.9
Anterior 42.1 51.9
Lateral 31.6 19.8
Hypertension (%) 79 65.4
Diabetes (%) 36.8 14.8
PTCA (%) 57.9 45.7
Coronary artery bypass graft (%) 21.1 16.1
Sudden cardiac arrest (%) 21.1 5
Sudden cardiac death (%) 11 4
IVS [cm] Baseline examination < 1.2 68.4 70
> 1.2 31.6 30
Follow-up examination < 1.2 66.7 77.1
> 1.2 33.3 23
LVEDD [cm] Baseline examination < 5.6 84.2 77.5
5.6–6.0 15.8 12.5
> 6.0 0 10
Follow-up examination < 5.6 93.3 80.3
5.6–6.0 6.7 13.1
> 6.0 0 5
LVEF (%) Baseline examination 52 ± 10 49 ± 11
Follow-up examination 55 ± 5 50 ± 11,6
Complex ventricular nsVT 11 15
arrhythmia in history (%)
sVT 10.5 2.5
VF 11 5
Patients requiring treatment due to 23.3 20.9
complex ventricular arrhythmia (%)
IVS — intraventricular septum (< 1.2 cm — normal, > 1.2 cm — left ventricular hypertrophy), PTCA — percutaneous transluminal coronary angioplasty;
LVEDD — left ventricular end-diastolic diameter (< 5.6 cm — normal, > 5.6 cm — left ventricular dilation), LVEF — left ventricular ejection fraction,
nsVT — nonsustained ventricular tachycardia, sVT — sustained ventricular tachycardia, VF — ventricular fibrillation
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attention to acquired LQTS [10, 11]. There are only
limited data on the role of genetic abnormalities in
the pathophysiology of the acquired LQTS. Kubota
et al. [12] discovered a missense mutation in the
KCNQ1 gene with hypokalemia linked long QT and
ventricular tachycardia. Napolitano et al. [13] do-
cumented a heterozygotic mutation in the KCNQ1
gene with SCA after cisapride ingestion.
In patients after MI the prolonged QTc inte-
rval greater than 440 ms worsens the prognosis of
the disease [14]. It is necessary to find the clinical
factors which will be able to define the subgroup of
high risk patients, who may benefit from arrhythmia
preventive measures such as implantable cardiover-
ter defibrillators. The QT measurement on ECG is
not always a reliable surrogate marker for prolonged
Table 4. Holter ECG data in groups with and without the T2755875G mutation.
Variable Group with Group without
mutation  mutation
HRmin [min] Baseline examination 46±8 47±8
Follow-up examination 47±8 47±8
HRmax [min] Baseline examination 107±15 112±24
Follow-up examination 104±17 114±19
HRmean [min] Baseline examination 67±11 69±11
Follow-up examination 66±9 68±10
ST level (%) Baseline examination 11 11
Follow-up examination 13 16
Ventricular arrhythmia Baseline examination 0 10.5 6.3
(Lown class) (%) I 26.3 20
II 10.5 13.8
IVa 26.3 26.3
IVb 26.3 33.8
Follow-up examination 0 6.3 4.3
I 37.5 20.3
II 25 10.1
III 6.3 1.4
IVa 12.5 34.8
IVb 12.5 29
HRmin — minimum heart rate, HRmax — maximum heart rate, HRmean — mean heart rate, ST level — myocardial ischemia
Figure 2. Average values of QTc max in QT1 and QT2
before a single ventricular ectopic heartbeat at daytime.
Figure 3. Average values of QTc max in QT1 and QT2 before
a couplet of ventricular ectopic heartbeats at daytime.
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repolarisation. It is not an ideal metric for accurate
indication of clinical outcome as not all patients who
present the arrhythmia phenotype exhibit prolonged
QT interval and some unaffected individuals have pro-
longed QTc value. Moreover, QT interval varies with
gender, age, concurrent drug administration, electro-
lyte abnormalities and other diseases [15–17]. Mole-
cular genetics thus may play a complementary role in
defining arrhythmic risk in this subgroup of patients.
In this study we report novel mutations in the
KCNQ1 potassium channel gene. It is the first re-
port attempting to assess the genotype changes in
patients after prior myocardial infarction. We have
identified DNA mutations associated with post in-
farction ventricular arrhythmia by testing the hypo-
thesis that variants in the congenital LQTS dise-
ase genes might contribute to risk in post MI pa-
tients. Patients with the target phenotype were
screened for variants in this gene and the frequen-
cy of these variants was then determined and cor-
related with clinical data.
In our study, in order to obtain as reliable re-
sults as possible, we used the DNA Pointer System
which enabled us to carry out the MSSCP analysis.
As a matter of fact, this is a genotyping method
characterized by both a significantly higher sensi-
tivity in detecting point mutations in comparison to
the commonly used SSCP and high reproducibility
of test results [9, 18–20].
In this study the new mutations were found
both in exons and introns. Most of the available data
concern exonic mutations [5]. However there are
more and more data on intronic mutations and the-
ir role in phenotypic variants [21, 22].
The intronic mutation T2755875G found in
19 out of 100 patients after MI was associated with
SCA and sustained ventricular tachycardia. This is the
first study that describes this intronic mutation.
It seems that this novel mutation may promote ad-
verse ventricular arrhythmic events in patients after
myocardial infarction. Moreover in patients with
T2755875G, QTmax and QTd at peak heart rate are
significantly longer compared to controls.
The explanation of the observed correlation
between mutations in KCNQ1 introns and the
clinical data appears to be very interesting. It is
a commonly accepted fact that the effects of muta-
tions depend on their location in the gene. Howe-
ver, all too often, it is taken for granted that only
genetic alterations in the coding sequences, i.e. in
exons, have an impact on the clinical course of the
disease. Indeed, almost up to the present day, any
alterations in the non-coding sequences, i.e. in in-
trons, have been discarded beforehand as irrelevant
because of the assumption that if intronic they do
not take part in the protein biosynthesis process.
On the other hand, recent studies and findings have
shown that intronic mutations may play a major role
in the splicing process, alter its course, lead to co-
ding sequence abnormalities and consequently in-
fluence the structure and function of the encoded
proteins. Numerous data reported in scientific pa-
pers show that both intronic and exonic alterations
may result in an aberrant splicing process, leading
to the formation of abnormal proteins, what in turn
affects the severity of the disease symptoms. The-
se data concern not only conventional splice sites
and regulatory splicing elements such as exonic
splicing enhancers (ESE), exonic splicing silencers
(ESS), intronic splicing enhancers (ISE), intronic
splicing silencers (ISE), but even deep intronic
mutations [23–26]. Consequently, genetic altera-
tions occurring in introns, in particular those rela-
ted to clinical symptoms, as in the case of post-MI
patients having the T2755875G intronic mutation,
can no longer be ignored. The role of this mutation
in the clinical course of the disease is corroborated
by the values of statistical p-levels obtained while
comparing this group of subjects to that without any
such genetic alterations in the KCNQ1 gene.
It is also worthwhile to turn our attention to
the influence of additional factors (such as drugs,
ischemia, electrolyte imbalance, increased adrener-
gic activity) on the risk of life-threatening ventri-
cular arrhythmia in subjects with mutations. This
issue has been largely discussed in scientific papers
[12, 13, 27–29]. It is not known, in fact, whether the
carriers of detected genetic alterations in the group
Figure 4. An example of multitemperature single strand
information polymorphism results.
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of patients after MI incur a greater risk of mali-
gnant ventricular arrhythmia on exposure to addi-
tional environmental factors propitious to electri-
cal instability of the myocardium, in comparison
with healthy subjects. And although the coronary
artery disease, including the MI, is partly geneti-
cally determined (influence of several genes), the
impact of a single mutation may prove to be insuffi-
cient to engender a life-threatening ventricular ar-
rhythmia. On the other hand, if the said mutation is
concomitant with additional environmental factors,
there is an increase of the risk of life-threatening
ventricular arrhythmia and consequently of sudden
cardiac death. It is therefore important to assess not
only traditional but also genetic SCD risk factors in
patients after myocardial infarction.
Genetic tests performed to this end might re-
veal the presence of genetic alterations in these
patients and allow the undertaking of preventive
steps such as: lifestyle modification, early imple-
mentation of adequate therapeutic measures in the
treatment of life-threatening ventricular arrhythmia
(cardioverter-defibrillator implantation), or creation
of new drugs improving the ion channel function.
Gene therapy could be the ultimate method of tre-
atment. It is worth extending genetic testing to the
relatives of probands and, in case they should have
the same genetic alterations, implementing prima-
ry prevention measures that they might avoid life-
threatening arrhythmia.
Conclusions
Summing up we discovered six new mutations
in the cardiac potassium gene KCNQ1: C2505734T
in exon 1, A2753831C in exon 12, C2505846A in
intron 1, G2753881A in intron 12, T2755854C and
T2755875G in intron 14. Detected intronic altera-
tions in patients after myocardial infarction were
related to a worse clinical course of the disease and
frequent occurrence of sudden cardiac arrests. The
novel intronic mutations in KCNQ1 found in our
study may have a significant influence on the clini-
cal course of the disease.
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